Susan Fox

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

Connie Lee Batlevi, Michael Crump, Charalambos Andreadis et al. · British Journal of Haematology · 2017 · 109 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

Christopher J. Sweeney, Stephen D. Williams, David Finch et al. · Cancer · 1999 · 65 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase II trial of paclitaxel in refractory germ cell tumors

Alan B. Sandler, Antonios Cristou, Susan Fox et al. · Cancer · 1998 · 54 citations · Full text

Medicine, Oncology, Pharmacotherapy +17